Syma Iqbal, MD

Articles

Dr. Iqbal on Determining Whether to Start With Regorafenib or TAS-102 in mCRC

December 3rd 2021

Syma Iqbal, MD, discusses determining whether to start with regorafenib (Stivarga) or trifluridine/tipiracil (TAS-102; Lonsurf) in metastatic colorectal cancer (mCRC).

Dr. Iqbal on the Emergence of Checkpoint Inhibitors in Upper GI Cancers

November 23rd 2021

Syma Iqbal, MD, discusses the emergence of checkpoint inhibitors in upper gastrointestinal cancers.

Dr. Iqbal on HER2-Driven Gastric Cancer

November 15th 2018

Syma Iqbal, MD, associate professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses the treatment of patients with HER2-driven gastric cancer.

Dr. Iqbal on the Biggest Advance in the Treatment of Neuroendocrine Tumors

November 6th 2018

Syma Iqbal, MD, associate professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses the impact of peptide receptor radionuclide therapy (PRRT) on the treatment of patients with neuroendocrine tumors (NETs).

Dr. Iqbal on Second- and Third-Line Therapies in Gastric Cancer

October 23rd 2018

Syma Iqbal, MD, associate professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses second- and third-line therapies in gastric cancer.

Dr. Iqbal on Treatment Options for Patients With Neuroendocrine Tumors

October 17th 2018

Syma Iqbal, MD, associate professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses treatment options for patients with neuroendocrine tumors (NETs).